Nirmatrelvir and Trospium / Xanomeline: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Trospium / Xanomeline
Nirmatrelvir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Your Cobenfy contains xanomeline, which can briefly slow down an enzyme in your gut called CYP3A4. Nirmatrelvir (part of the Paxlovid combination) is handled by that same enzyme. When the enzyme is slowed, a bit more of the nirmatrelvir can be absorbed, which may make its side effects (like an altered sense of taste, upset stomach, or diarrhea) show up more often or feel a little stronger.
The good news: this is based on how the drugs are expected to behave, not on proven cases. Your care team can easily keep an eye on you and adjust things if needed. Just let your pharmacist or doctor know you take both.
Effect: Xanomeline (in Cobenfy) transiently inhibits intestinal CYP3A4 without meaningful systemic inhibition. Because nirmatrelvir is a CYP3A4 substrate, gut-level inhibition may modestly increase its oral exposure (AUC/Cmax), potentially raising the frequency/severity of substrate-related adverse effects.
- Direction: increased nirmatrelvir exposure (neither drug is a prodrug here).
- Mechanism: inhibition of CYP3A4-mediated substrate metabolism by xanomeline.
- Onset: unspecified. Evidence: theoretical. Severity: moderate.
- Management: monitor for increased/severe substrate-related adverse reactions; dose may be individualized by the care team if warranted.
What happens
Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-related adverse reactions
Interaction Deep Dive
In the gut, xanomeline produces a temporary, local inhibition of CYP3A4, without exerting this effect systemically. When it is taken together with oral medications that are sensitive CYP3A4 substrates, the exposure to those oral sensitive CYP3A4 substrates may rise. Such an increase can raise how often and/or how severely adverse reactions from those substrates occur. During concurrent administration, patients should be watched for a greater frequency and/or severity of adverse reactions associated with oral drugs that are sensitive substrates of CYP3A41.
Why it happens (mechanism)
Inhibition of CYP3A4-substrate metabolism by xanomeline
How to manage this interaction
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This interaction is theoretical, so the usual approach is watchful monitoring rather than a fixed change.
- Watch for more frequent or stronger side effects of nirmatrelvir, such as altered taste, nausea, diarrhea, or stomach upset.
- Tell your pharmacist or prescriber that you take both, and report any new or worsening symptoms.
- Your team may monitor you more closely, and any dose can be adjusted and individualized if needed.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Nirmatrelvir and Trospium / Xanomeline together?
Xanomeline (Cobenfy) may slightly raise nirmatrelvir levels by slowing gut CYP3A4, so watch for more or stronger nirmatrelvir side effects and let your care team know you take both. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Nirmatrelvir and Trospium / Xanomeline interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Nirmatrelvir and Trospium / Xanomeline interaction managed?
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This interaction is theoretical, so the usual approach is watchful monitoring rather than a fixed change. Watch for more frequent or stronger side effects of nirmatrelvir, such as altered taste, nausea, diarrhea, or stomach upset. Tell your pharmacist or prescriber that you take both, and report any new or… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Nirmatrelvir or Trospium / Xanomeline need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Citation #1
Keep reading about Trospium / Xanomeline
Keep reading about Nirmatrelvir
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist